Comparisons of clinical efficacy and safety between the brand- and generic-name fenofibrate in patients with hypertriglyceridemia

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Generic-name drugs are chemically equivalent to their brand-name counterparts. However, the clinical efficacy and safety may not be equivalent between the brand-name (Lipanthyl) and generic-name (fenolip) fenofibrate in treating hypertriglyceridemia. The objective of this study was toinvestigate the efficacy and safety of brand- and generic-name fenofibrate in patients with hypertriglyceridemia. Methods: A total of 114 consecutive patients from January 2008 to December 2009 diagnosed with hypertriglyceridemia were enrolled in this study, including 57 patients receiving Lipanthyl (200mg/day) and another 57 patients treated with fenolip (200mg/day). Serum cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, glucose, creatinine, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were evaluated before and 3-6 months after the treatment. Results: With regard to clinical efficacy, both drugs were found to significantly decrease the serum levels of TG (297±125 to 165±73mg/dL, p

Original languageEnglish
Pages (from-to)136-138
Number of pages3
JournalJournal of Experimental and Clinical Medicine(Taiwan)
Volume5
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Fenofibrate
Hypertriglyceridemia
Names
Safety
Triglycerides
Generic Drugs
Aspartate Aminotransferases
Uric Acid
Serum
Alanine Transaminase
HDL Cholesterol
Creatinine
Cholesterol
Glucose
Pharmaceutical Preparations

Keywords

  • Brand-name drug
  • Fibrate
  • Generic-name drug
  • Triglyceride

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{23e6f208abd347ddb7ee083ae2d772c8,
title = "Comparisons of clinical efficacy and safety between the brand- and generic-name fenofibrate in patients with hypertriglyceridemia",
abstract = "Background: Generic-name drugs are chemically equivalent to their brand-name counterparts. However, the clinical efficacy and safety may not be equivalent between the brand-name (Lipanthyl) and generic-name (fenolip) fenofibrate in treating hypertriglyceridemia. The objective of this study was toinvestigate the efficacy and safety of brand- and generic-name fenofibrate in patients with hypertriglyceridemia. Methods: A total of 114 consecutive patients from January 2008 to December 2009 diagnosed with hypertriglyceridemia were enrolled in this study, including 57 patients receiving Lipanthyl (200mg/day) and another 57 patients treated with fenolip (200mg/day). Serum cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, glucose, creatinine, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were evaluated before and 3-6 months after the treatment. Results: With regard to clinical efficacy, both drugs were found to significantly decrease the serum levels of TG (297±125 to 165±73mg/dL, p",
keywords = "Brand-name drug, Fibrate, Generic-name drug, Triglyceride",
author = "Huang, {Jen Hung} and Cheng, {Ho Shun} and Chung, {Cheng Chih} and Hsieh, {Ming Hsiung}",
year = "2013",
month = "8",
doi = "10.1016/j.jecm.2013.06.012",
language = "English",
volume = "5",
pages = "136--138",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "4",

}

TY - JOUR

T1 - Comparisons of clinical efficacy and safety between the brand- and generic-name fenofibrate in patients with hypertriglyceridemia

AU - Huang, Jen Hung

AU - Cheng, Ho Shun

AU - Chung, Cheng Chih

AU - Hsieh, Ming Hsiung

PY - 2013/8

Y1 - 2013/8

N2 - Background: Generic-name drugs are chemically equivalent to their brand-name counterparts. However, the clinical efficacy and safety may not be equivalent between the brand-name (Lipanthyl) and generic-name (fenolip) fenofibrate in treating hypertriglyceridemia. The objective of this study was toinvestigate the efficacy and safety of brand- and generic-name fenofibrate in patients with hypertriglyceridemia. Methods: A total of 114 consecutive patients from January 2008 to December 2009 diagnosed with hypertriglyceridemia were enrolled in this study, including 57 patients receiving Lipanthyl (200mg/day) and another 57 patients treated with fenolip (200mg/day). Serum cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, glucose, creatinine, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were evaluated before and 3-6 months after the treatment. Results: With regard to clinical efficacy, both drugs were found to significantly decrease the serum levels of TG (297±125 to 165±73mg/dL, p

AB - Background: Generic-name drugs are chemically equivalent to their brand-name counterparts. However, the clinical efficacy and safety may not be equivalent between the brand-name (Lipanthyl) and generic-name (fenolip) fenofibrate in treating hypertriglyceridemia. The objective of this study was toinvestigate the efficacy and safety of brand- and generic-name fenofibrate in patients with hypertriglyceridemia. Methods: A total of 114 consecutive patients from January 2008 to December 2009 diagnosed with hypertriglyceridemia were enrolled in this study, including 57 patients receiving Lipanthyl (200mg/day) and another 57 patients treated with fenolip (200mg/day). Serum cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, glucose, creatinine, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were evaluated before and 3-6 months after the treatment. Results: With regard to clinical efficacy, both drugs were found to significantly decrease the serum levels of TG (297±125 to 165±73mg/dL, p

KW - Brand-name drug

KW - Fibrate

KW - Generic-name drug

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=84883459611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883459611&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2013.06.012

DO - 10.1016/j.jecm.2013.06.012

M3 - Article

AN - SCOPUS:84883459611

VL - 5

SP - 136

EP - 138

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 4

ER -